CVS Group
CVSG · Main Market · Health Care · mcap £790m · 1183.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | TVR & Confirmation of Dividend Dates
Share buyback completed; total voting rights now 67,460,830 ordinary shares; final dividend dates confirmed. |
−1.7% | |
| 24 Sep 26 | Results | Final Results
Revenue £712.8m up 5.9%, adjusted EBITDA £141.5m up 5.1%, Australian operations expanded to 57 sites. |
−6.2% |
| 23 Jul 26 | Trading update | Full year trading update
FY26 revenue grew 5.9% to £712.8m, adjusted EBITDA £141.5m in line with consensus; Australian expansion continues. |
−6.9% |
| 26 May 26 | Changes to NEDs' Responsibilities
Laura Hagan appointed Senior Independent Director and Employee Engagement Director from 1 July 2026, succeeding Deborah Kemp who retires. |
+5.8% | |
| 26 May 26 | Commencement of Share Buyback Programme
CVS launches £50m share buyback programme to return surplus capital to shareholders. |
+5.8% | |
| 26 May 26 | Refinancing, Launch of SBB and Acquisition
CVS refinanced £350m bank debt on improved terms, launched £50m share buyback programme, and acquired a small animal practice in Australia. |
+5.8% | |
| 21 Apr 26 | Board change | Non-Executive Director Appointment
Laura Hagan appointed as Independent Non-Executive Director effective 1 May 2026. |
−0.6% |
| 30 Mar 26 | Board change | CEO retirement
CEO Richard Fairman to retire; will remain in post until successor appointed. |
−1.6% |
| 25 Mar 26 | Board change | Non-Executive Director Changes
Two Independent Non-Executive Directors appointed, one retiring, Nomination Committee Chair changes. |
+0.5% |
| 24 Mar 26 | Response to CMA Summary Final Decision Report
CMA final decision on veterinary services concluded with no new remedies beyond provisional decision. |
+1.2% | |
| 26 Feb 26 | Results | Half-year Results
H1 2026 revenue up 5.8% to £356.9m; adjusted EBITDA up 3.9% to £67.7m; Australia expansion continues. |
−4.1% |
| 29 Jan 26 | Readmission - CVS Group Plc
NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM |
−2.5% | |
| 28 Jan 26 | Response to DEFRA consultation
CVS welcomes DEFRA consultation on reform of Veterinary Surgeons Act 1966, a CMA-recommended remedy. |
+0.3% | |
| 11 Dec 25 | Update on move to the Main Market
CVS Group to move from AIM to Main Market of London Stock Exchange on 29 January 2026. |
−0.8% | |
| 28 Nov 25 | Director dealing | SAYE Option Scheme & PDMR Dealing
Executive directors granted SAYE scheme options as part of employee share scheme; 370,637 total options granted at 10% discount. |
+2.5% |
| 18 Nov 25 | Trading update | AGM Statement and Trading Update
("CVS" or the "Company" and, together with its subsidiaries, the "Group") |
+0.0% |
| 24 Oct 25 | Commencement of Share Buyback Programme
CVS commences £20 million share buyback programme to be completed by Q1 2026. |
−2.9% | |
| 24 Oct 25 | Intention to move to Main Market & Buyback Scheme
CVS Group announces intention to move from AIM to Main Market and launches £20m buyback programme. |
−2.9% | |
| 15 Oct 25 | Response to CMA provisional decision announcement
CMA publishes provisional decision in veterinary market investigation with 21 proposed remedies; CVS to respond and implement measures. |
−0.7% | |
| 07 Oct 25 | Results | Final Results
Revenue grew 5.4% to £673.2m; like-for-like sales up 0.2%; adjusted EBITDA up 9.4% to £134.6m. |
+9.6% |
Company filings. Not investment advice.